Schizophrenia/Psychosis is a neurological disease that affects 0.32% of the world’s population. The onset of symptoms tends to occur during late adolescence through the twenties, and men tend to experience symptoms earlier than women. There are a variety of symptoms and not all are experienced by every person diagnosed with psychosis. The symptoms are classified as the positive and negative symptoms. Positive symptoms refer to the presence of hallucinations, delusions, disorganized speech, and trouble concentrating. The negative symptoms refer to a lack of normal function, lack of pleasure, trouble with speech, flattening, withdrawal, and lack of motivation. Current anti-psychotic medications come with “Black-box Warning” and can induce severe adverse effects, and frequently extrapyramidal motor disorders and hormonal disorders. Herbal medicines offer an alternative treatment to the currently used anti-psychotics with possible significant pharmacological actions and minimal adverse effects. Bacopa monneiri (Brahmi) has exhibited neuroprotective effects and can be a possible alternative therapy for psychosis. Bacopa monneiri belongs to the Scrophulariaceae family. Bacopa monnieri exhibit multiple central nervous system (CNS) activities and has shown to increase learning and memory, possess anxiolytic affects, and anti-epileptic affect. However, the anti-psychotic mechanisms of action are not well elucidated. Hence, the specific aim was to validate the anti-psychotic mechanisms of action of Bacopa monnieri using in-silico studies and perform a meta-analysis. In-silico studies and systematic reviews (using appropriate keywords on scientific platforms such as Google Scholar, PubMed, and various other online scientific research journals) will be conducted. Thus, validating the pharmacodynamic action of Bacopa monnieri can result in a natural product with potent pharmacological activity and insignificant adverse reactions. 

Keywords: Psychosis, Bacopa monnieri, Anti-psychotic, in-silico, meta-analysis, neuroprotective